Skip to main content
Effect of BMY-28100, a new cephalosporin, on Staphylococcus aureus nasal carriage
Quantitative Health Sciences Publications and Presentations
  • R. L. Atmar, Baylor College of Medicine
  • M. L. Allen, Baylor College of Medicine
  • J. Freiman, Baylor College of Medicine
  • Catarina I. Kiefe, University of Massachusetts Medical School
  • S. Ehrman, Baylor College of Medicine
  • S. B. Greenberg, Baylor College of Medicine
UMMS Affiliation
Department of Quantitative Health Sciences
Publication Date
Document Type
Adult; Carrier State; Cephalosporins; Humans; Male; Nasal Cavity; Staphylococcal Infections; Staphylococcus aureus

In order to examine the in vivo activity of BMY-28100, serial quantitative nasal cultures were taken from 52 nasal carriers of Staphylococcus aureus following administration of the antimicrobial. Nasal carriage rates and mean log titers decreased significantly during (days 2-4 and 5-8) and following (days 1-2 and 6-7) treatment. No change in antibiotic sensitivities was noted in follow-up isolates, and the MIC90 remained at 2mcg/ml. BMY-28100 demonstrated good in vivo activity against Staphylococcus aureus.

Eur J Clin Microbiol. 1987 Dec;6(6):679-81.
PubMed ID
Related Resources
Link to Article in PubMed
Citation Information
R. L. Atmar, M. L. Allen, J. Freiman, Catarina I. Kiefe, et al.. "Effect of BMY-28100, a new cephalosporin, on Staphylococcus aureus nasal carriage" Vol. 6 Iss. 6 (1987) ISSN: 0722-2211 (Linking)
Available at: